Long noncoding RNA
            <i>RUSC1-AS1</i>
            promotes tumorigenesis in cervical cancer by acting as a competing endogenous RNA of microRNA-744 and consequently increasing Bcl-2 expression

Guo, Qizhen; Zhang, Qin; Lu, Lianwei; Xu, Yuan

doi:10.1080/15384101.2020.1749468

Cited by 23 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, abnormal expression of DSCR8 is associated with poor prognosis in the liver (Wang et al, 2018) and ovarian cancer (You et al, 2020). Abnormal expression of RUSC1-AS1 has also been implicated in the development of cervical cancer (Guo et al, 2020). FGD5-AS1 has been shown to promote colorectal cancer cell proliferation, migration, and invasion by functioning as a sponge for miR-302e and regulating CDCA7 expression FIGURE 9 | GSEA and GSVA in high-and low-risk osteosarcoma patients.…”

Section: Discussionmentioning

confidence: 99%

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

Zhang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

BackgroundOsteosarcoma is a frequent bone malignancy in children and young adults. Despite the availability of some prognostic biomarkers, most of them fail to accurately predict prognosis in osteosarcoma patients. In this study, we used bioinformatics tools and machine learning algorithms to establish an autophagy-related long non-coding RNA (lncRNA) signature to predict the prognosis of osteosarcoma patients.MethodsWe obtained expression and clinical data from osteosarcoma patients in the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and Gene Expression Omnibus (GEO) databases. We acquired an autophagy gene list from the Human Autophagy Database (HADb) and identified autophagy-related lncRNAs by co-expression analyses. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the autophagy-related lncRNAs were conducted. Univariate and multivariate Cox regression analyses were performed to assess the prognostic value of the autophagy-related lncRNA signature and validate the relationship between the signature and osteosarcoma patient survival in an independent cohort. We also investigated the relationship between the signature and immune cell infiltration.ResultsWe initially identified 69 autophagy-related lncRNAs, 13 of which were significant predictors of overall survival in osteosarcoma patients. Kaplan-Meier analyses revealed that the 13 autophagy-related lncRNAs could stratify patients based on their outcomes. Receiver operating characteristic curve analyses confirmed the superior prognostic value of the lncRNA signature compared to clinically used prognostic biomarkers. Importantly, the autophagy-related lncRNA signature predicted patient prognosis independently of clinicopathological characteristics. Furthermore, we found that the expression levels of the autophagy-related lncRNA signature were significantly associated with the infiltration levels of different immune cell subsets, including T cells, NK cells, and dendritic cells.ConclusionThe autophagy-related lncRNA signature established here is an independent and robust predictor of osteosarcoma patient survival. Our findings also suggest that the expression of these 13 autophagy-related lncRNAs may promote osteosarcoma progression by regulating immune cell infiltration in the tumor microenvironment.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

Zhang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…It is also reported to serve as a prognostic indicator of hepatocellular carcinoma (HCC) [ 9 ] and promote HCC proliferation through regulating the NOTCH signaling pathway [ 39 ]. Besides, RUSC1-AS1 serves as a ceRNA in cervical cancer by binding with miR-744 and thus increases the expression of the anti-apoptotic protein BCL-2 [ 10 ]. In laryngeal squamous cell carcinoma, RUSC1-AS1 is also reported to be a ceRNA as well as a prognostic indicator [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

“…LncRNA RUSC1-AS1 is reported to promote tumor growth in hepatocellular carcinoma [ 9 ], cervical cancer [ 10 ] and breast cancer [ 11 ]. Zhang et al reported that RUSC1-AS1 is associated with unfavorable prognosis in osteosarcoma [ 12 ], but its role has not been studied yet.…”

Section: Introductionmentioning

confidence: 99%

LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway

Tong

Deng

et al. 2021

Aging

View full text Add to dashboard Cite

Dysregulation of long noncoding RNA (lncRNA) is frequently involved in the progression and development of osteosarcoma. LncRNA RUSC1-AS1 is reported to be upregulated and acts as an oncogene in hepatocellular carcinoma, cervical cancer and breast cancer. However, its role in osteosarcoma has not been studied yet. In the present study, we investigated the role of RUSC1-AS1 in osteosarcoma both in vitro and in vivo . The results showed that the expression of RUSC1-AS1 was significantly upregulated in osteosarcoma cell line U2OS and HOS compared to that in human osteoblast cell line hFOB1.19. Similar results were found in human samples. Silencing RUSC1-AS1 by siRNA significantly inhibited U2OS and HOS cell proliferation and invasion, measured by CCK-8 and transwell assay. Besides, knockdown of RUSC1-AS1 increased cell apoptosis in osteosarcoma cell lines. In addition, RUSC1-AS1 promoted the epithelial-mesenchymal transition (EMT) process of osteosarcoma cells. In vivo experiments confirmed that RUSC1-AS1 knockdown had an inhibitory effect on osteosarcoma tumor growth. Mechanically, we showed that RUSC1-AS1 directly binds to and inhibits miR-340-5p and activates the PI3K/AKT signaling pathway. In conclusion, our study demonstrated that RUSC1-AS1 promoted osteosarcoma development both in vitro and in vivo through sponging to miR-340-5p and activating the PI3K/AKT signaling pathway. Therefore, RUSC1-AS1 becomes a potential therapeutic target for osteosarcoma.

show abstract

“…The extemporaneous examination of the hysterectomy specimen is not recommended, as the speci city is low on myometrial in ltration and the histological grade. [44]. Analysis of the operative specimen after para n embedding allows in 25% of cases a grade change between the biopsy and the operative specimen and in 5% of cases a histological change and speci es the FIGO stage, myometrial invasion, the macroscopic size of the tumor, the depth of the invasion, the lymph node invasion, the presence of vascular emboli, the extension to the uterine cervix and the ectopic extension.…”

Section: Anatomopathological Pro Lementioning

confidence: 99%

Epidemiology and management of endometrial cancer: experience of International University Hospital Cheikh Khalifa and Mohammed VI Center for cancer treatment at University Hospital Ibn Rochd Casablanca, Morocco

Bouziyane¹,

Benaguida²,

Lamsisi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Endometrial cancer is the fourth most common cancer in women in high-income countries and its incidence has increased over the past 20 to 30 years. In Morocco, the incidence is close to those found in developing countries, but it is lower than those found in Western countries. To determine some epidemiological aspects of endometrial cancer in Morocco, we conducted a prospective study over 43 months at the International University Hospital Cheikh Khalifa and the Mohammed VI Center for Cancer Treatment at the Ibn Rochd Casablanca University Hospital, Morocco. 93 cases of endometrial cancer were included. Results The average age was 64. 36.5% of our patients had early menarche. 17.2% had menstrual cycle abnormalities. The nulliparous patients represent 40.8℅. 3 patients in our series underwent medical hormone treatment. 46.2% of patients claimed to have taken oral contraception during their period of genital activity, 79.5℅ were obese, 62.3% of the patients are diabetic and 49.4% are known to be hypertensive. 9.6% of patients are on hormone therapy with Tamoxifen. Metrorrhagia is the first symptom encountered in 62.2% of cases. Ultrasound was performed on all of our first-line patients and pelvic MRI was the most relevant examination in the pre-therapeutic assessment of endometrial cancer. Endometrial adenocarcinoma of the endometriotic type (81.72%) was the most prominent histological type. The therapeutic attitudes practiced were: Extended total colpohysterectomy for 17 patients. Total hysterectomy with bilateral salpingo-oophorectomy for 93 patients. Omentectomy was performed for 11 patients. 78 patients had undergone pelvic lymph node dissection, while 51 patients had undergone an associated lumbarortic dissection. 44.08℅ of cases were diagnosed at stage (IA) and 18.27℅ of cases at stage (III). At the time when we stopped our study, 42 patients had received radiotherapy as adjuvant treatment, ie 45.1% of cases. Conclusions Local and locoregional epidemiological studies should be multiplied to shed light on the interest of prevention by promoting a healthy lifestyle. Besides, genetic studies must be conducted to better understand the place of racial factors as risk factors for this cancer.

show abstract

Long noncoding RNA RUSC1-AS1 promotes tumorigenesis in cervical cancer by acting as a competing endogenous RNA of microRNA-744 and consequently increasing Bcl-2 expression

Cited by 23 publications

References 40 publications

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients

LncRNA RUSC1-AS1 promotes osteosarcoma progression through regulating the miR-340-5p and PI3K/AKT pathway

Epidemiology and management of endometrial cancer: experience of International University Hospital Cheikh Khalifa and Mohammed VI Center for cancer treatment at University Hospital Ibn Rochd Casablanca, Morocco

Contact Info

Product

Resources

About